| Literature DB >> 29731425 |
Carlos Moreno-Yruela1, Iacopo Galleano1, Andreas S Madsen1, Christian A Olsen2.
Abstract
Histone deacetylase (HDAC) enzymes regulate diverse biological function, including gene expression, rendering them potential targets for intervention in a number of diseases, with a handful of compounds approved for treatment of certain hematologic cancers. Among the human zinc-dependent HDACs, the most recently discovered member, HDAC11, is the only member assigned to subclass IV. It is the smallest protein and has the least well understood biological function. Here, we show that HDAC11 cleaves long-chain acyl modifications on lysine side chains with remarkable efficiency. We further show that several common types of HDAC inhibitors, including the approved drugs romidepsin and vorinostat, do not inhibit this enzymatic activity. Macrocyclic hydroxamic acid-containing peptides, on the other hand, potently inhibit HDAC11 demyristoylation activity. These findings should be taken carefully into consideration in future investigations of the biological function of HDAC11 and will serve as a foundation for the development of selective chemical probes targeting HDAC11.Entities:
Keywords: HDAC11; deacylation; enzyme inhibitors; enzyme kinetics; epigenetics; histone deacetylase; myristoylation; post-translational modification; protein acetylation; protein acylation
Mesh:
Substances:
Year: 2018 PMID: 29731425 DOI: 10.1016/j.chembiol.2018.04.007
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116